Related Experiment Video
Updated: Jan 12, 2026
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Astaxanthin limits atherosclerosis and dysmetabolism in mice by attenuating inflammatory cell recruitment and
Nathaly Anto-Michel1, Clemens Diwoky2, Katharina Pfeil1
1Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria.
Insights
Astaxanthin (ASX) reduces atherosclerosis and metabolic syndrome in mice by decreasing leukocyte recruitment and inflammation. This antioxidant shows promise for treating cardiovascular and metabolic diseases.
Area of Science:
- Cardiovascular Research
- Metabolic Disease Research
- Nutraceutical Science
Background:
- Astaxanthin (ASX) exhibits cardioprotective effects, including reduced body weight, adipose tissue, hypertension, and oxidative stress.
- Mechanisms underlying ASX's cardioprotective actions, particularly in atherosclerosis and metabolic derangements, require further elucidation.
Purpose of the Study:
- To investigate the role of astaxanthin (ASX) in mitigating experimental atherosclerosis and diet-induced metabolic syndrome in mice.
- To elucidate the biological mechanisms through which ASX exerts its therapeutic effects.
Main Methods:
- Ldlr-/- mice were fed a high-fat, high-cholesterol diet and treated with ASX or vehicle.
- Glucose and insulin tolerance tests assessed metabolic function.
- Aortic plaque size, lipid content, immune cell infiltration, and inflammatory signaling pathways were analyzed.
Main Results:
- ASX treatment significantly reduced atherosclerotic lesion size and M1 macrophage content in the aorta.
- Mice treated with ASX exhibited improved glucose metabolism, insulin sensitivity, and reduced peripheral monocyte and adipose tissue leukocyte abundance.
- ASX attenuated leukocyte recruitment to the vessel wall and dampened inflammatory signaling via Mitogen-activated protein kinases.
Conclusions:
- Astaxanthin (ASX) effectively reduces experimental atherosclerosis and ameliorates features of the metabolic syndrome in mice.
- The therapeutic effects of ASX are attributed to reduced leukocyte recruitment and systemic/local inflammation.
- These findings support the potential of ASX as a therapeutic agent for atherosclerosis and metabolic diseases, warranting clinical investigation.
Introduction:
Astaxanthin (ASX) has demonstrated various cardioprotective effects, including reductions in body weight, adipose tissue mass, hypertension, myocardial infarct size, and oxidative stress markers. Despite these findings, the underlying mechanisms remain unclear. This study examines the role of ASX in murine atherosclerosis and metabolic derangements induced by atherogenic diet, aiming to gain a deeper understanding of its biological effects and potential therapeutic applications.
Methods:
Ldlr-/- mice were fed a high-fat, high-cholesterol diet (HCD) for 16 weeks, receiving 70 mg/kg ASX or vehicle every other day. A week before the study ended, glucose and insulin tolerance tests were performed. Plaque size in the aorta was analyzed via histology (Oil-red-O and Masson's trichrome). Flow cytometry assessed immune cells from blood, aorta, adipose tissue, and cytokines in plasma. Additional mice underwent intravital microscopy for further investigation.
Results:
The overall body weight of animals treated with ASX or vehicle did not differ. ASX-treated mice showed a reduced abundance of peripheral monocytes by 34%, lower numbers of leukocytes in adipose tissue depots, and improved glucose metabolism and insulin sensitivity compared with animals receiving vehicle. White adipose mass decreased while brown adipose and muscle mass increased in mice treated with ASX. Atherosclerotic lesions of Ldlr-/- mice receiving ASX were significantly smaller and contained fewer lipids (3.3 vs 2.6 x 105 µm2) and M1 macrophages (0.97 vs 0.42x103) but increased collagen, in line with a more stable plaque phenotype. Mechanistic experiments revealed that ASX attenuated leukocyte recruitment (43% ± 1.87) to the vessel wall in intravital microscopy and dampened inflammatory signaling through Mitogen-activated protein kinases.
Conclusion:
ASX treatment reduces experimental atherosclerosis and blunts metabolic syndrome features in mice. This effect is linked to reduced leukocyte recruitment and systemic/local inflammation. The findings support ASX's potential in treating atherosclerosis and metabolic diseases, offering new mechanistic insights and ultimately warrant the rigorous clinical evaluation of such putative effects.
Related Concept Videos
01:26Atherosclerosis III: Management
01:38Inflammation
01:30Atherosclerosis I: Introduction